ClinicalTrials.gg
RecruitingNCT07367113PPI-PROTECTUpdated Apr 9, 2026

Peripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients

An interventional study of Peripheral Perfusion Index-guided Fluid Resuscitation Protocol and Conventional Goal-Directed Fluid Resuscitation in Sepsis, Septic Shock and Acute Skin Failure, sponsored by Ying Wang. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ying Wang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2025, registered Jan 2026).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Shock, Septic with a site in China — 30 open to participants now, 32 under way, 1 of them phase 3. Shock, Septic · China.

Planned enrollment
19th of 62
216 · median 72
Started
2025
with 6 others
No phase
41 of 89
15 open now
Primary completion
2026-12
later than 12 of 31 live
Registered
74th of 89
by date

Among the 89 studies in Shock, Septic with a site in China, this one is the 19th largest by planned enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2025, is one of 41 with no phase, reaches primary completion later than 12 of the 31 other live ones, and was the 74th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

30 of the 89 studies in Shock, Septic with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Shock, Septic with a site in China, or all of them as a file.
02

Study summary

This prospective, randomized, controlled trial aimed to evaluate whether fluid resuscitation guided by the Peripheral Perfusion Index (PPI) could reduce the incidence of Acute Skin Failure (ASF) in elderly critically ill patients. A total of 216 patients aged ≥65 years with sepsis or other types of shock requiring early aggressive fluid resuscitation were enrolled and randomly assigned in a 1:1 ratio to either the PPI-guided resuscitation group or the conventional resuscitation group. The intervention group targeted maintaining PPI ≥1.4 in addition to conventional hemodynamic goals, while the control group followed standard resuscitation protocols. The primary outcome was the incidence of ASF within 7 days of ICU admission, diagnosed according to NPUAP/EPUAP (2014) criteria. Secondary outcomes included time to ASF occurrence, lactate clearance, cumulative fluid balance, organ function, and long-term prognosis.

03

Conditions studied

  • Sepsis
  • Septic Shock
  • Acute Skin Failure

Browse trials for

04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 216 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Ying Wang is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years.
  2. Diagnosis of sepsis (according to Sepsis-3 criteria) or other types of shock requiring early and aggressive fluid resuscitation.
  3. APACHE II score ≥ 15 at ICU admission.
  4. Expected ICU length of stay ≥ 72 hours.
  5. Written obtained from the patient or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing stage III or higher pressure injury or skin necrosis at the time of enrollment.
  2. Severe dermatological disease or peripheral vascular disease that could interfere with the assessment of skin or peripheral perfusion.
  3. Inability to perform continuous finger pulse oximetry monitoring (e.g., due to bilateral finger injury, amputation, or severe peripheral edema).
  4. to liberal fluid resuscitation (e.g., acute cardiogenic pulmonary edema, severe heart failure with fluid overload).
  5. Expected survival \< 24 hours due to terminal illness or irreversible condition. Concurrent participation in another interventional clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    eripheral Perfusion Index-guided Fluid Resuscitation Protocol

    Other: Peripheral Perfusion Index-guided Fluid Resuscitation Protocol

  • Active comparator
    Conventional Fluid Resuscitation Group

    Other: Conventional Goal-Directed Fluid Resuscitation

Interventions

  • OtherPeripheral Perfusion Index-guided Fluid Resuscitation Protocol

    In addition to achieving conventional macro-hemodynamic goals (mean arterial pressure ≥65 mmHg, etc.), a resuscitation protocol targeting a Peripheral Perfusion Index (PPI) value ≥1.4 is implemented. PPI is continuously monitored via a finger pulse oximeter. If PPI remains below 1.4 for \>30 minutes, a fluid responsiveness assessment (e.g., passive leg raising test) is performed. Fluid boluses (balanced crystalloid) are administered only if the patient is fluid-responsive. Otherwise, vasoactive agents are optimized.

  • OtherConventional Goal-Directed Fluid Resuscitation

    Fluid resuscitation is performed according to the Surviving Sepsis Campaign International Guidelines. Resuscitation targets include: mean arterial pressure ≥65 mmHg, central venous pressure 8-12 mmHg, urine output ≥0.5 mL·kg-¹·h-¹, and normalization/decreasing trend of serum lactate. The type, rate, and volume of fluid administration are determined by the treating physician based on these standard macro-hemodynamic and perfusion parameters.

07

What researchers measure

Primary outcomes

  1. Incidence of Acute Skin Failure(per the NPUAP/EPUAP 2014 Guidelines)

    Proportion of patients who develop new-onset Acute Skin Failure (ASF) within 7 days after ICU admission. ASF is diagnosed and staged according to the NPUAP/EPUAP (2014) criteria.

    Time frame: From ICU admission up to 7 days

Secondary outcomes

  1. Time to Acute Skin Failure (ASF) Onset

    Number of days from ICU admission to the first diagnosis of ASF (assessed in patients who develop ASF)

    Time frame: From ICU admission up to 7 days

  2. Maximum Stage of Acute Skin Failure

    The most severe stage of ASF (according to NPUAP/EPUAP 2014 criteria) observed within 7 days after ICU admission

    Time frame: From ICU admission up to 7 days

  3. Lactate Clearance Rate at 6 Hours

    Percentage decrease in serum lactate concentration from baseline to 6 hours after initiation of resuscitation

    Time frame: Baseline and 6 hours after resuscitation initiation

  4. Lactate Clearance Rate at 24 Hours

    Percentage decrease in serum lactate concentration from baseline to 24 hours after initiation of resuscitation

    Time frame: Baseline and 24 hours after resuscitation initiation

  5. Cumulative Fluid Balance at 72 Hours

    Net fluid balance (total fluid intake minus total output) calculated over the first 72 hours of ICU stay

    Time frame: From ICU admission up to 72 hours

  6. Incidence of Acute Kidney Injury

    Proportion of patients who develop AKI according to KDIGO criteria within 7 days after ICU admission

    Time frame: From ICU admission up to 7 days

  7. Duration of Mechanical Ventilation

    Total number of days requiring invasive mechanical ventilation during ICU stay

    Time frame: From ICU admission until ICU discharge, up to 90 days

  8. Length of ICU Stay

    Total number of days from ICU admission to ICU discharge

    Time frame: From ICU admission until ICU discharge, up to 90 days

  9. 28-Day All-Cause Mortality

    Proportion of patients who die from any cause within 28 days after ICU admission

    Time frame: From ICU admission up to 28 days

  10. 90-Day All-Cause Mortality

    Proportion of patients who die from any cause within 90 days after ICU admission

    Time frame: From ICU admission up to 90 days

  11. Barthel Index at Hospital Discharge

    Score of the Barthel Index (a measure of activities of daily living) assessed at the time of hospital discharge in surviving patients. Range: 0-100, higher scores indicate greater independence

    Time frame: At hospital discharge, up to 90 days after ICU admission

  12. Total Hospitalization Costs

    Total direct medical costs incurred during the index hospitalization, expressed in local currency

    Time frame: From hospital admission to hospital discharge, up to 90 days

  13. 30-Day Unplanned Readmission Rate

    Proportion of patients who have an unplanned readmission to any hospital within 30 days after hospital discharge

    Time frame: 30 days after hospital discharge

  14. Incidence of Resuscitation-Related Serious Adverse Events

    Proportion of patients who experience serious adverse events related to fluid resuscitation (e.g., new-onset cardiogenic pulmonary edema, arrhythmia requiring intervention) during the ICU stay

    Time frame: From ICU admission until ICU discharge, up to 90 days

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — The investigators may have further research, and the investigators may not consider releasing the research data until the results are announced

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 23 months is close to that.

Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 26, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07367113
Lead sponsor
Ying Wang
Collaborators
Nantong First People's Hospital
Responsible party
Ying Wang (Clinical Professor, Nantong First People's Hospital) — Sponsor-investigator
First posted
Jan 26, 2026
Start date
Jan 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

Ying Wang
Contact
wenquxingdiyi@163.com
+86 13485139816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion